Hospital-acquired infections, (HAIs) have become far too prevalent across the nation. The statistics are grim. Ten million hospital patients will get an infection in a health care institution over the next five years and half a million of them will die. Many fear going to the hospital because that is where the most virulent microbes are encountered.
Along with MRSA, many significant infection-causing bacteria in the world are also becoming resistant to the most commonly prescribed antimicrobial treatments. Antimicrobial resistance occurs when bacteria change or adapt in a way that allows them to survive in the presence of antibiotics designed to kill them. In some cases bacteria become so resistant that no available antibiotics are effective against them. People infected with antibiotic-resistant organisms like MRSA are more likely to have longer and more expensive hospital stays, and may be more likely to die as a result of the infection. When the drug of choice for treating their infection doesn’t work, they require treatment with second- or third-choice medicines that may be less effective, more toxic and more expensive.
Antibiotic toxicity is just as serious a problem as resistance. Antibiotics have been shown to be chondrotoxic, damaging the body’s cartilage; neurotoxic, carcinogenic, nephrotoxic, and more. In fact, antibiotics are the principle cause of drug-associated nephropathy.
But there is a new weapon in the fight against resistant microbes. Microcyn technology is a safe-as-saline anti-infective that quickly eradicates a broad range of pathogens, including antibiotic-resistant bacteria (including MRSA and VRE), viruses, fungi and spores. Dual-action in nature, in addition to killing the infection, Microcyn also accelerates the wound-healing process by reducing inflammation in the wound and increasing nutrient-rich blood and oxygen flow to the wound bed. Twenty-five clinical studies have demonstrated Microcyn to be both safe and effective in killing pathogens.
What makes Microcyn so remarkably effective is the way hypochlorous acid works in tandem with reactive oxygen species. This is also the way the immune system’s neutrophils work, through oxidative burst. This is something no microbe can stand up to, nor can they develop resistance to it. Microcyn has been evaluated by the USP <51> Antimicrobial Effectiveness Test, now designated as a Category 1 product. The log reduction rates are spectacular. As a hygiene product it is unparalleled.
Microcyn has revolutionized wound care as we know it. A dramatic case of limb salvage when dealing with necrotizing fasciitis came to my attention just this week. A well known Infectious Disease specialist in Florida was fighting a losing battle against NF in a leg wound. Amputation was inevitable. However, the doctor became aware of Microcyn and called the company, requesting an emergency shipment. Microcyn irrigations were initiated and the leg was saved. The family was ecstatic. This is just one of many such cases.
The medical applications for Microcyn are too numerous to list here. Over two million people have been treated worldwide without a single report of a serious adverse effect.
FDA clearances are coming steadily through this year and next. We will most certainly be seeing more remarkable medical breakthroughs involving Microcyn.
If appropriate protocol using Microcyn were to be established in our health care institutions, the outcome would be far reaching indeed. It has the capability of preventing HAIs when used as a skin prep prior to surgery, an irrigant during surgery, and as an antiseptic for post-operative care. It also can be used as a nasal spray, ear drops, eye drops, and can eliminate catheter-associated urinary tract infections, (CAUTIs), by rinsing the bladder on a daily basis.
Microcyn is to the epidemic of HAIs what quinine was to malaria and the Salk vaccine to polio.
There is a great deal more to be said about this, but a picture is worth a thousand words: